These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 11522648

  • 21. Inhibitory effect of full-length human endostatin on in vitro angiogenesis.
    Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger HJ, Chiarugi V, Ramponi G.
    Biochem Biophys Res Commun; 1999 Sep 24; 263(2):340-5. PubMed ID: 10491294
    [Abstract] [Full Text] [Related]

  • 22. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH.
    Cancer Res; 2003 Aug 01; 63(15):4648-55. PubMed ID: 12907645
    [Abstract] [Full Text] [Related]

  • 23. NC1 domain of human type VIII collagen (alpha 1) inhibits bovine aortic endothelial cell proliferation and causes cell apoptosis.
    Xu R, Yao ZY, Xin L, Zhang Q, Li TP, Gan RB.
    Biochem Biophys Res Commun; 2001 Nov 23; 289(1):264-8. PubMed ID: 11708810
    [Abstract] [Full Text] [Related]

  • 24. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
    Pass J, Jögi A, Lund IK, Rønø B, Rasch MG, Gårdsvoll H, Lund LR, Ploug M, Rømer J, Danø K, Høyer-Hansen G.
    Thromb Haemost; 2007 Jun 23; 97(6):1013-22. PubMed ID: 17549305
    [Abstract] [Full Text] [Related]

  • 25. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J, Pilka R, Noskova V, Ehinger A, Domanski H, Andersson C, Høyer-Hansen G, Hansson SR, Casslén B.
    Mol Hum Reprod; 2004 Sep 23; 10(9):655-63. PubMed ID: 15243126
    [Abstract] [Full Text] [Related]

  • 26. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 23; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 27. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
    Ragno P, Montuori N, Covelli B, Hoyer-Hansen G, Rossi G.
    Cancer Res; 1998 Mar 15; 58(6):1315-9. PubMed ID: 9515821
    [Abstract] [Full Text] [Related]

  • 28. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F, D'Alessio S, Serratì S, Pucci M, Del Rosso A, Benelli R, Ferrari N, Noonan DM, Albini A, Fibbi G, Del Rosso M.
    Int J Oncol; 2005 Jul 15; 27(1):223-35. PubMed ID: 15942664
    [Abstract] [Full Text] [Related]

  • 29. High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells.
    Hedberg KK, Stauff C, Høyer-Hansen G, Rønne E, Griffith OH.
    Exp Cell Res; 2000 May 25; 257(1):67-81. PubMed ID: 10854055
    [Abstract] [Full Text] [Related]

  • 30. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U, Magdolen V, Hapke S, Schmitt M.
    Biol Chem; 2003 Aug 25; 384(8):1119-31. PubMed ID: 12974381
    [Abstract] [Full Text] [Related]

  • 31. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 25; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 32. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S, Lockett J, Meng Y, Biliran H, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, Cher ML, Sheng S.
    Cancer Res; 2006 Apr 15; 66(8):4173-81. PubMed ID: 16618739
    [Abstract] [Full Text] [Related]

  • 33. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE, Saunders DN, Ranson M.
    Breast Cancer Res; 2007 Apr 15; 9(1):R14. PubMed ID: 17257442
    [Abstract] [Full Text] [Related]

  • 34. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P, Vocca I, Carriero MV, Alfano D, Cito L, Longanesi-Cattani I, Grieco P, Ossowski L, Stoppelli MP.
    J Cell Sci; 2006 Aug 15; 119(Pt 16):3424-34. PubMed ID: 16882693
    [Abstract] [Full Text] [Related]

  • 35. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
    Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M.
    Clin Cancer Res; 2003 Nov 01; 9(14):5358-69. PubMed ID: 14614021
    [Abstract] [Full Text] [Related]

  • 36. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Nov 01; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 37. AIDS-related Kaposi's sarcoma cells rapidly internalize endostatin, which co-localizes to tropomysin microfilaments and inhibits cytokine-mediated migration and invasion.
    Mallery SR, Morse MA, Wilson RF, Pei P, Ness GM, Bradburn JE, Renner RJ, Schuller DE, Robertson FM.
    J Cell Biochem; 2003 May 01; 89(1):133-43. PubMed ID: 12682914
    [Abstract] [Full Text] [Related]

  • 38. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
    Zhang G, Cai X, López-Guisa JM, Collins SJ, Eddy AA.
    J Am Soc Nephrol; 2004 Aug 01; 15(8):2090-102. PubMed ID: 15284295
    [Abstract] [Full Text] [Related]

  • 39. Integrin alphavbeta3 is not significantly implicated in the anti-migratory effect of anti-angiogenic urokinase kringle domain.
    O E, Kim HK, Hong SH, Kim CK, Hong YK, Joe YA.
    Oncol Rep; 2008 Sep 01; 20(3):631-6. PubMed ID: 18695916
    [Abstract] [Full Text] [Related]

  • 40. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
    Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG.
    Cancer Res; 2000 Oct 01; 60(19):5410-3. PubMed ID: 11034081
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.